The FDA Just Outlawed CBDs and Hemp Oil Extracts by Claiming all Plant Molecules Now Belong Exclusively to Big Pharma.


http://ushealthtimes.com/the-fda-just-outlawed-cbds-and-hemp-oil-extracts-by-claiming-all-plant-molecules-now-belong-exclusively-to-big-pharma/

Advertisements

A Happiness Expert Says Changing Your Life for the Better Starts With an Uncomfortable Question.


https://www.thriveglobal.com/stories/12218-a-happiness-expert-says-changing-your-life-for-the-better-starts-with-an-uncomfortable-question?utm_source=Thrive&utm_medium=Facebook

10 mindful attitudes that rewire your brain to let go of anxiety.


https://hackspirit.com/10-mindful-attitudes-rewire-brain-let-go-anxiety/?utm_content=buffer4657c&utm_medium=share&utm_source=facebook&utm_campaign=msa

Nikola Tesla’s LOST papers—antigravity technology


http://ewao.net/2017/05/04/nikola-teslas-lost-papers-antigravity-technology/

THIS is the real reason why ancient civilizations built THOUSANDS of Pyramids


http://ewao.net/2017/05/08/this-is-the-real-reason-why-ancient-civilizations-built-thousands-of-pyramids/

Fighting cancer with nanobodies and computer simulations.


https://horizon-magazine.eu/article/fighting-cancer-nanobodies-and-computer-simulations_en.html

World Cancer Day- NGS Technologies.


https://www.m3india.in/contents/editor_pick/65030/world-cancer-day-ngs-technology-taking-cancer?utm_source=facebook&utm_medium=ads&utm_campaign=CP11_Article_Oncology_FB

Missing Neutrons May Lead a Secret Life as Dark Matter


This may be the reason experiments can’t agree on the neutron lifetime, according to a new idea.
Missing Neutrons May Lead a Secret Life as Dark Matter
Neutrons, the mundane-seeming inhabitants of atoms, could be hiding a secret connection to dark matter, according to a new proposal.

Neutrons shouldn’t be all that mysterious. Found inside every atomic nucleus, they may seem downright mundane—but they have long confounded physicists who try to measure how long these particles can live outside of atoms. For more than 10 years researchers have tried two types of experiments that have yielded conflicting results. Scientists have struggled to explain the discrepancy, but a new proposal suggests the culprit may be one of the biggest mysteries of all: dark matter.

Scientists are pretty sure the universe contains more matter than the stuff we can see, and their best guess is that it takes the form of invisible particles. What if neutrons are decaying into these invisible particles? This idea, put forward by University of California, San Diego, physicists Bartosz Fornal and Benjamin Grinstein in a paper posted this month to the physics preprint site arXiv.org, would explain why one type of neutron experiment consistently measures a different value than the other. If true, it could also provide the first way to access the dark matter particles physicists have long been seeking to no avail.

The idea has already gripped many researchers making neutron lifetime measurements, and some have quickly scrambled to look for evidence of it in their experiments. If neutrons are turning into dark matter, the process could also produce gamma-ray photons, according to Fornal and Grinstein’s calculations. “We have some germanium gamma-ray detectors lying around,” says Christopher Morris, who runs neutron experiments at Los Alamos National Laboratory. By serendipity, he and his team just recently installed a large tank to collect neutrons on their way from the start of the experiment to the point where physicists try to measure their lifetimes. This tank provided a large holding cell where many neutrons might decay into dark particles, if the process in fact occurs, and produce gamma-rays as a by-product. “When we heard about this paper, we took our detector and set it up next to our big tank and started looking for gamma rays.” He and his team are still analyzing the results of this trial, but hope to have a paper out in a few weeks reporting on what they found.

Only one of the two types of neutron decay experiments would be sensitive to neutrons decaying into dark matter. This type, called “bottle experiments,” essentially puts a given number of neutrons into a “bottle” with magnetic walls that holds them inside, then counts how many are left after a certain amount of time. Through many measurements the researchers can calculate how long an average neutron lives.

The other type of experiment looks for the main product of neutron decays. Through a well-known process called beta decay, a neutron outside of an atomic nucleus will break down into a proton, an electron and an antimatter neutrino. So-called “beam” experiments shoot a beam of neutrons into a magnetic trap that catches positively charged protons. Researchers count how many neutrons go in and how many protons come out after a given time, then infer the average time it takes a neutron to decay.

Both classes of experiments find neutrons can last for only about 15 minutes outside of atoms. But bottle experiments measure an average of 879.6 seconds plus or minus 0.6 second, according to the Particle Data Group, an international statistics-keeping collaboration. Beam experiments get a value of 888.0 seconds plus or minus 2.0 seconds. The 8.4-second difference may not seem like much, but it is larger than either of the calculations’ margins of error—which are based on the experimenters’ understanding of all the sources of uncertainty in their measurements. The difference leaves the two figures with a statistically significant “4-sigma” deviation. Experimenters behind both methods have scoured their setups for overlooked problems and sources of uncertainty, with no luck so far.

But if neutrons can transform in more ways than just beta decay, it would explain why bottle and beam experiments do not find the same answers. Fornal and Grinstein suggest that occasionally neutrons turn into some type of dark particle, undetectable by traditional means. The bottle experiments would then measure a slightly shorter lifetime for the neutron than beam experiments, because the former would be counting the dark matter decays in addition to the beta decays—and thus detecting a larger number of total decays in any given time period. The beam setup, however, only measures how long it takes neutrons to turn into protons, so their tally would not include dark matter decays and would therefore suggest neutrons can stick around slightly longer. And that is indeed what the two methods show.

“It would be nice to have an explanation,” says Peter Geltenbort, who runs bottle experiments at the Institut Laue–Langevin in France. If the dark particle idea is correct, “it means that we experimentalists are giving the right error for our measurements. People have written that maybe we are just too optimistic estimating our systematic [uncertainties], but it would confirm that we did a good job.” Geltenbort is also collaborating with Morris on the Los Alamos bottle experiments.

Perhaps the larger implication—if neutron experiments show any evidence for the dark particle hypothesis—is that physicists might then have a link to dark matter. The dark particle that Fornal and Grinstein propose could be the same particle that makes up the cosmos’ missing mass. It could also be a different invisible particle, perhaps part of some larger sector of numerous dark particles. “They [Fornal and Grinstein] are building a very specific set of models to explain the neutron lifetime discrepancy,” says dark matter theorist Peter Graham of Stanford University. “It’s not obvious that their models really fit into any other dark matter models that people have built for other reasons.” For the neutron to decay into a dark particle, for instance, that particle must be lighter than the neutron’s mass of around 940 MeV/c2 (mega–electron volts divided by the speed of light squared). On the other hand, one of the most popular classes of theorized dark matter particles, so-called weakly interacting massive particles (WIMPs), would weigh somewhere around 100 GeV/c2 (giga–electron volts divided by the speed of light squared)—roughly 100 times more than a neutron.

Fornal first started thinking about the neutron enigma about a year ago. “I ran into an article by Peter Geltenbort about this mysterious discrepancy between the neutron lifetime measurements,” and thought, “wow, that’s a really big thing to explain,” he says. The article was an adaptation of an April 2016 Scientific American story Geltenbort had authored with University of Tennessee Knoxville physicist Geoffrey Greene that was published in the Institut Laue–Langevin’s annual report. Fornal says he was reminded of the topic a few months ago, when he and Grinstein came across a reference to it. “We didn’t find any theoretical model explaining this, and thought it might be an interesting thing to do,” he says. The researchers worked on the hypothesis over the holidays and posted their paper online just after the new year. They are surprised—but thrilled—that they might know soon whether or not neutron decay experiments see evidence for their proposal. “[neutron researchers] started looking for this so quickly,” Fornal says. “It’s nice to hear that this theory is not disconnected from experiments.”

Big Pharma Has the Flu


Flu vaccines make pharma companies $3 billion a year and aren’t very effective. Without a Manhattan Project-style initiative to modernize immunizations, things aren’t going to get any better.

A week ago, the Centers for Disease Control and Prevention confirmed what people have been suspecting: This flu season is one of the worst in recent memory. It’s on track to match the 2014-2015 season in which 34 million Americans got the flu, and about 56,000 people—including 148 children—died.

One reason behind the high toll is a mismatch between one of the flu viruses infecting people and one of the viral strains chosen almost a year ago for the global vaccine recipe, which gets rewritten every year. The dominant strain this winter is one called H3N2, which historically causes more severe illness, hospitalizations, and deaths than other strains. When the flu swept through Australia last summer, the effectiveness of the H3N2 component of the vaccine was only about 10 percent. The CDC doesn’t yet have a hard estimate for effectiveness in the United States but thinks it might be near 30 percent.

That mismatch is a bad piece of biological luck. But we should consider it a warning.

We’ve long known that our flu vaccines aren’t built to last, or to tackle every strain. But pharma companies don’t have an incentive to research drugs that will make them less money—not while current vaccines are good enough to make them $3 billion a year. To drive those new vaccines forward, medicine needs a Manhattan Project-style investment, pulling on resources outside the drug industry to force a new generation of vaccines into existence.

It’s well-known inside medicine, and little appreciated outside it, that flu vaccines aren’t as protective as most people assume. In January, the CDC collated data on flu-vaccine effectiveness from 2004 up through last year. There was no flu season in which the vaccine protected more than 60 percent of recipients. In the worst season, 2004-2005, effectiveness sank to 10 percent. That’s very different from childhood vaccines. As Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, lamented at a meeting last summer: “The measles, mumps, and rubella vaccine is 97 percent effective; yellow fever vaccine is 99 percent effective.”

The flu virus itself is to blame. The measles virus that threatens a child today is no different from the one that circulated 50 years ago, so across those 50 years, the same vaccine formula has worked just fine. But flu viruses—and there are always a few around at once—change constantly, and each year vaccine formulators must race to catch up.

The dream is to develop a “universal flu vaccine,” one that could be given once or twice in toddlerhood like an MMR vaccine, or boosted a few times in your life as whooping-cough shots are. That is a substantial scientific challenge because the parts of the flu virus that don’t change from year to year—and thus could evoke long-lasting immunity—are hidden away in the virus, masked by the parts that change all the time.

A handful of academic teams are competing to build such a new shot. They’re tinkering with the proteins that protrude from the virus, trying to take off their ever-changing heads so the immune system can respond to their conserved, unchanging stalks. They’re creating chimeric viruses from several proteins fused together, and they’re emptying out viral envelopes or engineering nanoparticles to provoke immunity in unfamiliar ways. Several of those strategies look promising in animal studies but haven’t been tested in humans. There are substantial hurdles to putting any formula into a human arm—including the fundamental one of figuring out what level of immune reaction signals that a new formula is protective enough.

And then, of course, there’s the fact that creating a new vaccine is expensive. It includes not just the cost of research and development, clinical trials, and licensing—generally accepted, across the pharma industry, to take 10 to 15 years and about $1 billion—but also the price tag for building a new manufacturing facility, which can top $600 million. Contrast that to the expenses of making the current vaccines, which use equipment and processes not changed in decades. A 2013 World Health Organization analysis pegged each manufacturers’ cost of refreshing the annual vaccine at $5 million to $18 million per year.

Now consider this: Right now, millions of people, roughly 100 million just in the United States, receive the flu vaccine every year. If those shots were converted to once or twice or four times in a lifetime, manufacturers would lose an enormous amount of sales and would need to price a new vaccine much higher per dose to recoup.

“What’s the business model here? Am I going to spend more than $1 billion to make a vaccine when I can only sell $20 million worth of doses?” Michael Osterholm asks.

The founder of the University of Minnesota’s Center for Infectious Disease Research and Policy, and a former adviser to the Secretary of Health and Human Services, Osterholm has been pushing for years to get people to notice that the market structure for the flu vaccine works against innovation. “Think about this,” he told me. “If you get a licensed product, which can take billions of dollars to achieve, how are you going to get a return on investment unless you are able to charge an exorbitant amount?”

This isn’t a hypothetical. Take the case of FluMist: As Osterholm’s CIDRAP group revealed in a 2012 report, The Compelling Need for Game-Changing Influenza Vaccines, the vaccine manufacturer MedImmune expended more than $1 billion to develop the novel nasal-spray flu vaccine. In 2009, its first year on the market, FluMist earned just $145 million. And in 2016 and 2017, a CDC advisory body recommended against using the spray at all, saying its rate of effectiveness had sunk to 3 percent.

Examples such as FluMist, Osterholm’s group wrote in their report, make it unlikely that any manufacturer will embark on a new flu vaccine or that VCs will fund them. “We could find no evidence that any private-sector investment source, including venture capital or other equity investors or current vaccine manufacturers, will be sufficient to carry one, yet alone multiple, potential novel-antigen influenza vaccines across the multiyear expenses of production,” they wrote.

As it happens, another sector of medicine is grappling with a similar problem. Since about 2000, pharma manufacturers have largely abandoned antibiotics because of a similar mismatch between investment and reward. Like vaccines, antibiotics are priced low and used for short amounts of time—unlike the lucrative cardiovascular or cancer drugs you’ll see advertised on TV and in magazines.

One answer to the funding gap has been a public-private research accelerator, CARB-X. It was founded in 2016 to dispense $455 million from the US government and a matching amount from the Wellcome Trust in England to support risky early stage research into new antibiotic compounds. Another proposal, put forward by the British Review on Antimicrobial Resistance but not yet enacted, would give roughly $1 billion in no strings “market entry rewards” to companies that get new compounds all the way through trials to licensure, counting on the cash grant to repay R&D expenses.

Osterholm thinks flu vaccines need research support, market rewards, sales guarantees, and more—a matrix of investment in research, manufacturing, and research leadership that he likens to the Manhattan Project, the all-in federal effort to build atomic bombs to bring an end to World War II. Only governments have the power to organize that scale of project, he thinks, and only private philanthropy, on the scale of the Gates Foundation or the Wellcome Trust, has the resources and the flexibility.

And he may be right. What’s clear is that the current flu vaccine market is broken. It’s important to think about that now, because this flu season marks the 100th anniversary of the worst flu known to history: The world-spanning 1918 influenza, which killed an estimated 100 million people in little more than a year. Flu pandemics arrive irregularly, and no one has been able to predict when the worst of them will come again. It would be smart of us to fix the vaccine problem before it arrives.

The Next 25 Years of WIRED Start Today


In the first issue of WIRED, published 25 years ago this year, founding editor Louis Rossetto declared that “in the age of information overload, THE ULTIMATE LUXURY IS MEANING AND CONTEXT.” (Caps his.) If anything, that simple observation rings even truer today. That’s why WIRED has always valued depth. We dig deep into our subjects, reveling in wonky engineering details that other publications skip. We think deep thoughts about the future. And we form deep relationships with our audience—connecting them to a community of ideas and encouraging them to think harder about the future they want to inhabit.

For most of our history our business model, primarily built on advertising, rewarded that depth. Advertisers are eager to connect with our sophisticated audience, and WIRED remains the best way to reach them. But in recent years, that industry has proven fickle and tumultuous, and a too-slender reed upon which to hang our entire business.

That’s why today we are launching a paywall—a business that rewards our connection to our audience and will help us keep WIRED a home for unique, surprising, challenging, and sophisticated journalism for the next quarter-century and beyond.

Careful readers may note here that, as the voice of the digital revolution, we have hewed to Stewart Brand’s famous notion that “information wants to be free,” a declaration that some have interpreted to mean that nobody should ever pay for digital content. But read the rest of Brand’s statement: “On the one hand, information wants to be expensive, because it is so valuable,” he told Steve Wozniak in 1984. “The right information in the right place just changes your life. On the other hand, information wants to be free, because the cost of getting it out is getting lower and lower all the time. So you have these two fighting against each other.” That tension persists today. Even as information has become cheap or free to distribute, we believe that quality information—built on great reporting, vivid writing, and illuminating insight—remains valuable.

By subscribing to WIRED, you can help us continue our legacy of fresh insights, deep reporting, stunning design, and beautiful writing. The details are here, but in a nutshell: If you read four articles in a month, you will be invited to subscribe to read further. If you subscribe, you not only get unlimited access to WIRED.com and a print subscription, you’ll also receive a free YubiKey—a crucial tool for protecting yourself online. You’ll get access to a digital edition of our magazine, delivered fresh to your tablet every month. And when you visit us online, we’ll take out the ads.

But the real benefit of your subscription is that you’ll ensure that we can continue producing great stories and content. To that end, we want to announce three new programs we’re launching with the paywall. First, we’re happy to introduce the all-new Backchannel—a home for our most ambitious digital long-form journalism. Our long features are routinely the most popular on our site, and that’s why we are building a special home for them—and doubling our investment in producing them.

Next, we’d like to unveil our new Ideas section. WIRED has always prided itself on what we call mind grenades—expansive, surprising ideas that change the way the world thinks. We are now dedicating a section of our website to publishing the biggest ideas from the most exciting thinkers in the world—including MIT MediaLab head Joi Ito, Magic and Loss author Virginia Heffernan, Big Chicken author Maryn McKenna, and Jason Pontin, the former editor of MIT Technology Review.

Finally, we are unleashing an entirely new kind of story—WIRED Guides. These are definitive, authoritative guides to the most important subjects in the WIRED world. Need an update on the state of drone technology? Don’t know the difference between supervised and unsupervised artificial intelligence? Want to finally understand how the blockchain works? WIRED Guides have you covered, with enlightening essays and links to great stories from WIRED’s unparalleled archives.

For a quarter-century, WIRED has watched as the internet has rewritten everything about journalism and media—who creates it, what we expect from it, and how we support it. And yet, at heart, Louis’ central observation in our launch issue is as true today as it was 25 years ago—when mere information is cheap and plentiful, context and meaning are more valuable than ever. The paywall refocuses our business around that simple truth.

%d bloggers like this: